Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 37, 678-683, March 1, 1977]
© 1977 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Avery, T. L.
Right arrow Articles by Roberts, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Avery, T. L.
Right arrow Articles by Roberts, D.

Adriamycin and Cyclophosphamide in Combination Chemotherapy of L1210 Leukemia1

Thomas L. Avery2 and DeWayne Roberts

Laboratories of Pharmacology, St. Jude Children's Research Hospital, Memphis, Tennessee 38101

Combinations of cyclophosphamide and adriamycin, encompassing a wide range of dosages, were administered on five different schedules to C57BL/6J x DBA/2J F1 female mice inoculated i.p. with L1210 ascites tumor cells. Among the resulting 85 treatment groups, the mean postinoculation survival of mice that died with tumor was 11.4 to 51.3 days; this represented increases of 62 to 628% over the survival of untreated controls. In some groups, tumor cells were eradicated in 9 of 10 treated mice. By contrast, neither drug given alone cured leukemic mice or extended their survival beyond controls by more than 96%. Adriamycin and cyclophosphamide were most effective when administered simultaneously on Day 1; additional treatment with adriamycin on Days 4 and 7 produced a significant increase in the survival of mice that died with tumor, but this regimen did not increase the incidence of cures. Combination therapy with these agents reduced the cytotoxic response of the host to subsequently inoculated L1210 cells. The pronounced therapeutic effectiveness of this drug combination is attributed to a true potentiation of the independent oncolytic action of each agent.

1 Supported by Childhood Cancer Research Center Grant CA-08480 and Research Project Grant CA-12732, both from the National Cancer Institute, NIH, and by ALSAC.

2 To whom requests for reprints should be addressed, at St. Jude Children's Research Hospital, P. O. Box 318, Memphis, Tenn. 38101.

Received 8/18/75. Accepted 12/ 3/76.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1977 by the American Association for Cancer Research.